18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Metaanalysis

作者：Ashwin Singh Parihar, Sofia C. Vaz, Siobhan Sutcliffe, Niharika Pant, J. Schoones, Gary A. Ulaner · 发表于：Journal of Nuclear Medicine · 年份：2025 · DOI：10.2967/jnumed.124.269163 · 被引用次数：7 · 研究领域：Medicine

Visual Abstract 18F-fluoroestradiol (18F-FES) PET/CT has been investigated as a potential biomarker to predict response to endocrine therapies in patients with estrogen receptor (ER)–positive breast cancer. Although previous findings were promising, most had limited statistical significance because of small individual sample sizes. Therefore, we performed a systematic review and metaanalysis of the 18F-FES PET/CT literature to increase our power to evaluate the utility of 18F-FES PET/CT as a biomarker for prediction of clinical benefit from endocrine therapy in patients with ER-positive breast cancer. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, MEDLINE via OVID, Embase, Web of Science, Emcare, and the Cochrane Central Register of Controlled Trials through November 1, 2024, for studies that included patients with ER-positive breast cancer who received an 18F-FES PET/CT at baseline and received subsequent endocrine therapy. For each eligible study, data were extracted using a predesigned data extraction form. Random effects models were used to estimate the likelihood of clinical benefit from endocrine therapy after a positive 18F-FES PET scan, the likelihood of clinical benefit from endocrine therapy after a negative 18F-FES PET scan, and the risk ratio of clinical benefit from endocrine therapy comparing those who were 18F-FES–positive to those who were 18F-FES–negative. Results: From 1,105 database records retrieved, 1...